Biologics and cell therapy tissue engineering approaches for the management of the edentulous maxilla: A systematic review

Gustavo Avila-Ortiz, P. Mark Bartold, William Giannobile, Wataru Katagiri, Salvador Nares, Hector Rios, Daniel Spagnoli, Ulf M E Wikesjö

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Purpose: The aim of this systematic review was to evaluate current and emerging regenerative approaches for implant site development in the edentulous atrophic maxilla using tissue engineering and regenerative medicine (TERM) principles and to identify priorities for future research. Materials and Methods: Two independent examiners conducted a comprehensive search using specific keywords to identify original clinical studies using TERM for implant site development in the edentulous atrophic maxilla including indications for alveolar ridge preservation, horizontal alveolar augmentation, maxillary sinus augmentation, and augmentation of severe vertical or combined defects. Endpoints included clinical, radiographic, histologic, and patient-centered outcomes. Results: The initial search identified 3,061 articles. The final selection included 89 articles, of which 12 evaluated alveolar ridge preservation, 6 horizontal defects, 61 maxillary sinus augmentation, and 11 management of severe vertical or combined defects. A summary of the main findings relative to the effect of TERM-based approaches applied for implant site development in the atrophic maxillary segments is presented. Marked heterogeneity among included studies prevented meaningful quantitative analysis. The following relevant effects of TERM-based therapies for site development in the edentulous atrophic maxilla were observed: (1) recombinant human bone morphogenetic protein-2 in an absorbable collagen sponge carrier increased bone augmentation; (2) recombinant human platelet-derived growth factor BB in combination with freeze-dried bone allograft or beta tricalcium phosphate accelerated bone formation through accelerated remodeling of carrier biomaterials; (3) autologous cell therapy enhanced clinical and radiographic outcomes; (4) autologous cell therapy in alveolar ridge preservation provided superior histomorphometric outcomes (vital bone formation) at 6 weeks; and (5) platelet-rich plasma formulations combined with autologous bone grafts for maxillary sinus augmentation increased radiographic density and accelerated bone mineralization at 6 months. Conclusion: Clinical success has been demonstrated with the application of different TERM modalities for implant site development in the edentulous atrophic maxilla. However, indications are narrow and further study is needed. Clinical trials assessing meaningful outcomes, involving larger populations, and with longer follow-up are warranted to discern the effectiveness of the achieved results compared with a valid control.

Original languageEnglish (US)
Pages (from-to)121-164
Number of pages44
JournalInternational Journal of Oral and Maxillofacial Implants
Volume31
DOIs
StatePublished - Jan 1 2016

Fingerprint

Biological Therapy
Regenerative Medicine
Maxilla
Tissue Engineering
Cell- and Tissue-Based Therapy
Alveolar Process
Maxillary Sinus
Osteogenesis
Bone and Bones
Physiologic Calcification
Platelet-Rich Plasma
Porifera
Biocompatible Materials
Allografts
Collagen
Clinical Trials
Transplants
Population

Keywords

  • Atrophic maxillae
  • Biological agents
  • Cell-and tissue-based therapy
  • Dental implants
  • Implant-supported dental prosthesis
  • Tissue engineering

ASJC Scopus subject areas

  • Oral Surgery

Cite this

Biologics and cell therapy tissue engineering approaches for the management of the edentulous maxilla : A systematic review. / Avila-Ortiz, Gustavo; Mark Bartold, P.; Giannobile, William; Katagiri, Wataru; Nares, Salvador; Rios, Hector; Spagnoli, Daniel; Wikesjö, Ulf M E.

In: International Journal of Oral and Maxillofacial Implants, Vol. 31, 01.01.2016, p. 121-164.

Research output: Contribution to journalArticle

Avila-Ortiz, Gustavo ; Mark Bartold, P. ; Giannobile, William ; Katagiri, Wataru ; Nares, Salvador ; Rios, Hector ; Spagnoli, Daniel ; Wikesjö, Ulf M E. / Biologics and cell therapy tissue engineering approaches for the management of the edentulous maxilla : A systematic review. In: International Journal of Oral and Maxillofacial Implants. 2016 ; Vol. 31. pp. 121-164.
@article{a811965f0878433a9ec59320022259c2,
title = "Biologics and cell therapy tissue engineering approaches for the management of the edentulous maxilla: A systematic review",
abstract = "Purpose: The aim of this systematic review was to evaluate current and emerging regenerative approaches for implant site development in the edentulous atrophic maxilla using tissue engineering and regenerative medicine (TERM) principles and to identify priorities for future research. Materials and Methods: Two independent examiners conducted a comprehensive search using specific keywords to identify original clinical studies using TERM for implant site development in the edentulous atrophic maxilla including indications for alveolar ridge preservation, horizontal alveolar augmentation, maxillary sinus augmentation, and augmentation of severe vertical or combined defects. Endpoints included clinical, radiographic, histologic, and patient-centered outcomes. Results: The initial search identified 3,061 articles. The final selection included 89 articles, of which 12 evaluated alveolar ridge preservation, 6 horizontal defects, 61 maxillary sinus augmentation, and 11 management of severe vertical or combined defects. A summary of the main findings relative to the effect of TERM-based approaches applied for implant site development in the atrophic maxillary segments is presented. Marked heterogeneity among included studies prevented meaningful quantitative analysis. The following relevant effects of TERM-based therapies for site development in the edentulous atrophic maxilla were observed: (1) recombinant human bone morphogenetic protein-2 in an absorbable collagen sponge carrier increased bone augmentation; (2) recombinant human platelet-derived growth factor BB in combination with freeze-dried bone allograft or beta tricalcium phosphate accelerated bone formation through accelerated remodeling of carrier biomaterials; (3) autologous cell therapy enhanced clinical and radiographic outcomes; (4) autologous cell therapy in alveolar ridge preservation provided superior histomorphometric outcomes (vital bone formation) at 6 weeks; and (5) platelet-rich plasma formulations combined with autologous bone grafts for maxillary sinus augmentation increased radiographic density and accelerated bone mineralization at 6 months. Conclusion: Clinical success has been demonstrated with the application of different TERM modalities for implant site development in the edentulous atrophic maxilla. However, indications are narrow and further study is needed. Clinical trials assessing meaningful outcomes, involving larger populations, and with longer follow-up are warranted to discern the effectiveness of the achieved results compared with a valid control.",
keywords = "Atrophic maxillae, Biological agents, Cell-and tissue-based therapy, Dental implants, Implant-supported dental prosthesis, Tissue engineering",
author = "Gustavo Avila-Ortiz and {Mark Bartold}, P. and William Giannobile and Wataru Katagiri and Salvador Nares and Hector Rios and Daniel Spagnoli and Wikesj{\"o}, {Ulf M E}",
year = "2016",
month = "1",
day = "1",
doi = "10.11607/jomi.16suppl.g4",
language = "English (US)",
volume = "31",
pages = "121--164",
journal = "The International journal of oral & maxillofacial implants",
issn = "0882-2786",
publisher = "Quintessence Publishing Company",

}

TY - JOUR

T1 - Biologics and cell therapy tissue engineering approaches for the management of the edentulous maxilla

T2 - A systematic review

AU - Avila-Ortiz, Gustavo

AU - Mark Bartold, P.

AU - Giannobile, William

AU - Katagiri, Wataru

AU - Nares, Salvador

AU - Rios, Hector

AU - Spagnoli, Daniel

AU - Wikesjö, Ulf M E

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Purpose: The aim of this systematic review was to evaluate current and emerging regenerative approaches for implant site development in the edentulous atrophic maxilla using tissue engineering and regenerative medicine (TERM) principles and to identify priorities for future research. Materials and Methods: Two independent examiners conducted a comprehensive search using specific keywords to identify original clinical studies using TERM for implant site development in the edentulous atrophic maxilla including indications for alveolar ridge preservation, horizontal alveolar augmentation, maxillary sinus augmentation, and augmentation of severe vertical or combined defects. Endpoints included clinical, radiographic, histologic, and patient-centered outcomes. Results: The initial search identified 3,061 articles. The final selection included 89 articles, of which 12 evaluated alveolar ridge preservation, 6 horizontal defects, 61 maxillary sinus augmentation, and 11 management of severe vertical or combined defects. A summary of the main findings relative to the effect of TERM-based approaches applied for implant site development in the atrophic maxillary segments is presented. Marked heterogeneity among included studies prevented meaningful quantitative analysis. The following relevant effects of TERM-based therapies for site development in the edentulous atrophic maxilla were observed: (1) recombinant human bone morphogenetic protein-2 in an absorbable collagen sponge carrier increased bone augmentation; (2) recombinant human platelet-derived growth factor BB in combination with freeze-dried bone allograft or beta tricalcium phosphate accelerated bone formation through accelerated remodeling of carrier biomaterials; (3) autologous cell therapy enhanced clinical and radiographic outcomes; (4) autologous cell therapy in alveolar ridge preservation provided superior histomorphometric outcomes (vital bone formation) at 6 weeks; and (5) platelet-rich plasma formulations combined with autologous bone grafts for maxillary sinus augmentation increased radiographic density and accelerated bone mineralization at 6 months. Conclusion: Clinical success has been demonstrated with the application of different TERM modalities for implant site development in the edentulous atrophic maxilla. However, indications are narrow and further study is needed. Clinical trials assessing meaningful outcomes, involving larger populations, and with longer follow-up are warranted to discern the effectiveness of the achieved results compared with a valid control.

AB - Purpose: The aim of this systematic review was to evaluate current and emerging regenerative approaches for implant site development in the edentulous atrophic maxilla using tissue engineering and regenerative medicine (TERM) principles and to identify priorities for future research. Materials and Methods: Two independent examiners conducted a comprehensive search using specific keywords to identify original clinical studies using TERM for implant site development in the edentulous atrophic maxilla including indications for alveolar ridge preservation, horizontal alveolar augmentation, maxillary sinus augmentation, and augmentation of severe vertical or combined defects. Endpoints included clinical, radiographic, histologic, and patient-centered outcomes. Results: The initial search identified 3,061 articles. The final selection included 89 articles, of which 12 evaluated alveolar ridge preservation, 6 horizontal defects, 61 maxillary sinus augmentation, and 11 management of severe vertical or combined defects. A summary of the main findings relative to the effect of TERM-based approaches applied for implant site development in the atrophic maxillary segments is presented. Marked heterogeneity among included studies prevented meaningful quantitative analysis. The following relevant effects of TERM-based therapies for site development in the edentulous atrophic maxilla were observed: (1) recombinant human bone morphogenetic protein-2 in an absorbable collagen sponge carrier increased bone augmentation; (2) recombinant human platelet-derived growth factor BB in combination with freeze-dried bone allograft or beta tricalcium phosphate accelerated bone formation through accelerated remodeling of carrier biomaterials; (3) autologous cell therapy enhanced clinical and radiographic outcomes; (4) autologous cell therapy in alveolar ridge preservation provided superior histomorphometric outcomes (vital bone formation) at 6 weeks; and (5) platelet-rich plasma formulations combined with autologous bone grafts for maxillary sinus augmentation increased radiographic density and accelerated bone mineralization at 6 months. Conclusion: Clinical success has been demonstrated with the application of different TERM modalities for implant site development in the edentulous atrophic maxilla. However, indications are narrow and further study is needed. Clinical trials assessing meaningful outcomes, involving larger populations, and with longer follow-up are warranted to discern the effectiveness of the achieved results compared with a valid control.

KW - Atrophic maxillae

KW - Biological agents

KW - Cell-and tissue-based therapy

KW - Dental implants

KW - Implant-supported dental prosthesis

KW - Tissue engineering

UR - http://www.scopus.com/inward/record.url?scp=84985945808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84985945808&partnerID=8YFLogxK

U2 - 10.11607/jomi.16suppl.g4

DO - 10.11607/jomi.16suppl.g4

M3 - Article

C2 - 27228246

AN - SCOPUS:84985945808

VL - 31

SP - 121

EP - 164

JO - The International journal of oral & maxillofacial implants

JF - The International journal of oral & maxillofacial implants

SN - 0882-2786

ER -